Loading stock data…
Novartis AG researches (NVS)
$155.01-1.13 (-0.72%)
Market ClosedLast close Jul 24
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Novartis AG in the Healthcare sector is trading at $155.01 with a market capitalization of $287.5B. Wall Street consensus targets $154.76 (10 analysts), implying a -0.2% move over the next 12 months. The stock is currently 9% below its 52-week high of $170.46, remaining 8.2% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $13.52B↓ | $13.86B↓ | $14.36B↓ | $14.84B↑ | $13.62B |
| Gross Profit | $10.06B↓ | $10.25B↓ | $10.82B↓ | $11.51B↑ | $10.39B |
| Operating Income | $4.24B↑ | $3.62B↓ | $4.50B↓ | $4.86B↑ | $4.66B |
| Net Income | $3.16B↑ | $2.41B↓ | $3.93B↓ | $4.04B↑ | $3.61B |
Peer Comparison
JNJUNHPFE
Fundamentals
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart f...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$287.55B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
3.08%
ROE
Elite ROE. Management converts capital into profit efficiently.
35.14%
Volume
Today's trading volume
1.72M
Recent News
Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner?
INCY heads into Q2 earnings with strong Jakafi demand, Opzelura momentum and rising royalties, fueling expectations for an earnings beat.
Big Pharma Is Buying Growth. Novartis (NVS) Is Betting on Its Pipeline
Big Pharma is buying its way out of the patent cliff, while Novartis AG (NYSE:NVS) is trying to out-develop it. A Record Year for Biotech Deals The scale of that buying activity appears in this year’s deal totals. Biotech M&A has hit a record pace in 2026, with deal value reaching $216 billion so far […]
Company News for July 22, 2026
Companies in The News Are: NVS, GM, SYF, MMM
Novartis (SWX:NOVN) Is Pushing AI Deeper Into Drug Discovery
Novartis (SWX:NOVN) CEO has outlined a bigger role for artificial intelligence across the company’s research and development activities. The company is expanding investment in AI tools with the aim of shortening drug development timelines and improving clinical trial success rates. The comments signal a broader push to use digital technologies across Novartis’s drug discovery and development pipeline. Novartis sits among the large global pharmaceutical companies focused on prescription...
Novartis (NVS) Q2 2026 Earnings Call Transcript
Growth drivers offset generic erosion as priority brands surge 36% in constant currency.